Prostate Cancer Drug Creator ICR Sees 6-Week Research Strike Threaten Breakthroughs

Every day that benches sit empty at the ICR, progress on the next generation of cancer therapies stalls. For a healthcare system that relies on home‑grown innovation, this strike raises the stakes: from delayed trial results to potential talent flight, the fallout could echo through oncology care for years.

The Institute of Cancer Research (ICR), a 117-year-old institution revered for landmark breakthroughs such as the development of the first advanced prostate cancer treatment Abiraterone, is in the grip of an unprecedented labor dispute. On June 3, 2026, staff—ranging from scientific researchers to porters, maintenance crews, and administrative workers—walked out for the first time in the institute’s history. The strike, now extended twice and set to run through August 7, has been described by union representatives as an 'existential crisis' for a research powerhouse that has shaped modern oncology.

“

The Institute of Cancer Research (ICR), a 117-year-old institution revered for landmark breakthroughs such as the development of the first advanced prostate cancer treatment Abiraterone, is in the grip of an unprecedented labor dispute.

The core of the conflict is a collapsed incremental pay model. Union Unite accuses management of engaging in 'hostile' negotiations, presenting four offers that were essentially repurposed versions of the first, while intentionally delaying meetings. The union is demanding the reinstatement of annual step-based pay increases that recognize experience and rising living costs, alongside broader pay restoration. Pensions protection has been agreed upon, but the pay structure dispute remains unresolved. Personal testimony from Aiden Doyle, a 37-year-old higher scientific officer at the ICR’s Children’s Brain Tumour Centre of Excellence, underscores the financial distress: without a recent promotion, he would have had to sell his flat and return to renting. He and his wife—both committed to cancer research—now find themselves at a 'snapping point.' Disturbingly, some staff have taken second jobs to make ends meet, a stark contradiction for professionals at a globally significant research center.

The strike’s temporal scale is significant. Initially set for 65 days from June 3 to August 7, it already represents a protracted disruption. For a laboratory‑driven organization, every lost day means stalled experiments, delayed data generation, and interrupted clinical trial activities. The ICR’s pipeline relies on continuity: cell cultures die, reagents expire, and animal studies face ethical re‑evaluation. Even a short pause can set back projects by months, and the longer the walkout continues, the harder it is to regain momentum. The reputational damage extends beyond immediate research. The institute competes internationally for top talent and funding; a public labor crisis may deter future recruits and worry grant‑giving bodies.

The dispute also reflects wider structural tensions in UK research funding. The ICR is a charity and a member institution of the University of London, but its salary policies are directly influenced by national pay frameworks and evolving public‑sector austerity. Researchers and support staff are confronting a cost‑of‑living crisis that has eroded real wages over a decade. The claim that staff are becoming 'poorer' the longer they stay points to a broken career ladder—seniority is no longer rewarded with financial security, undermining the appeal of long‑term roles in academia and public‑interest research.